Abbott Laboratories (NYSE:ABT) CFO Purchases $201,300.00 in Stock

Abbott Laboratories (NYSE:ABT) CFO Philip Boudreau bought 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Abbott Laboratories Stock Down 2.5%

Abbott Laboratories stock opened at $91.52 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a 1-year low of $90.72 and a 1-year high of $139.06. The company has a market cap of $159.40 billion, a PE ratio of 25.64, a price-to-earnings-growth ratio of 1.55 and a beta of 0.79. The stock’s 50 day moving average price is $104.76 and its 200 day moving average price is $116.38.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the previous year, the business earned $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. Abbott Laboratories’s payout ratio is 70.59%.

Hedge Funds Weigh In On Abbott Laboratories

Several large investors have recently added to or reduced their stakes in the business. Seelaus Asset Management LLC lifted its position in Abbott Laboratories by 2.0% during the first quarter. Seelaus Asset Management LLC now owns 6,273 shares of the healthcare product maker’s stock worth $644,000 after buying an additional 125 shares during the period. IAG Wealth Partners LLC lifted its position in Abbott Laboratories by 43.1% during the first quarter. IAG Wealth Partners LLC now owns 531 shares of the healthcare product maker’s stock worth $54,000 after buying an additional 160 shares during the period. Staley Capital Advisers Inc. lifted its position in Abbott Laboratories by 11.8% during the first quarter. Staley Capital Advisers Inc. now owns 7,457 shares of the healthcare product maker’s stock worth $766,000 after buying an additional 788 shares during the period. Nichols & Pratt Advisers LLP MA lifted its position in Abbott Laboratories by 23.4% during the first quarter. Nichols & Pratt Advisers LLP MA now owns 41,870 shares of the healthcare product maker’s stock worth $4,299,000 after buying an additional 7,950 shares during the period. Finally, Sageworth Trust Co lifted its position in Abbott Laboratories by 36.7% during the first quarter. Sageworth Trust Co now owns 27,828 shares of the healthcare product maker’s stock worth $2,857,000 after buying an additional 7,470 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ABT. Benchmark decreased their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Evercore decreased their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company decreased their price target on Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. BTIG Research reissued a “buy” rating and issued a $131.00 target price on shares of Abbott Laboratories in a report on Monday. Finally, UBS Group lowered their target price on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $119.43.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Insiders buying shares — Director Daniel Starks purchased 10,000 shares, a vote-of-confidence signal that can stabilize sentiment for long-term holders. SEC Form 4 – Daniel Starks purchase
• Positive Sentiment: CFO Philip Boudreau also bought shares (~2,200 at ~$91.50), which investors often read as management putting capital to work. CFO Philip Boudreau Buys 2,200 Shares
• Positive Sentiment: Regulatory win — Abbott received FDA clearance and a CE Mark for its Ultreon™ 3.0 AI coronary imaging software, strengthening the medtech growth story for high‑margin cardiovascular devices. Ultreon 3.0 FDA clearance and CE Mark
• Neutral Sentiment: Citi reaffirmed a buy rating — institutional analyst support may limit further downside but hasn’t fully offset concerns. Citi Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Neutral Sentiment: Active manager repositioning — Polen Focus Growth exited ABT in Q1, reflecting some portfolio-level rotation rather than company‑specific change. That can add short‑term selling pressure but is not a direct operational signal. Here’s Why Polen Focus Growth Exited Abbott Laboratories (ABT) in Q1
• Negative Sentiment: Guidance trimmed / acquisition dilution — Abbott narrowed FY26 EPS to $5.38–$5.58 and cited roughly $0.20 of dilution from the $21B Exact Sciences deal, a primary driver of the selloff and recent 52‑week lows. Q1 Earnings and Exact Sciences Acquisition Fallout
• Negative Sentiment: Analyst target cuts & device/diabetes softness — several firms trimmed price targets and highlighted near‑term weakness in diabetes and some medtech end markets, increasing downside risk until revenue mix normalizes. Analyst reaction and market commentary

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.